IB Ltd.

IB Ltd.

  • News & Announcements
  • Shareholder Information
  • Investor Relations
  • Significant Shareholders
  • Publications
  • Home
  • Corporate News & Announcements
  • IB Ltd News & Announcements
  • Director Dealings and Conversion of CLNs

Director Dealings and Conversion of CLNs

Monday, 15 January 2024 / Published in IB Ltd News & Announcements

Director Dealings and Conversion of CLNs

/**/
RNS Number : 6148Z
IQ-AI Limited
15 January 2024
 

IQ-AI Ltd

(“IQ-AI” or the “Company”)

 

Director Dealings and Conversion of Convertible Loan Notes

IQ-AI Ltd has received convertible loan note conversion notices from Trevor Brown, the CEO of IQ-AI, and Micheal Schmainda, a director of IQ-AI. Trevor Brown is converting a total of £60,000 convertible loan notes and associated interest, issued in May 2019, at a price of 1.5 pence, into 5,111,233 Ordinary Shares. Michael Schmainda is converting a total of £18,500 convertible loan notes and associated interest, issued in March 2019, at a price of 2 pence, into  1,193,681 Ordinary Shares which will be issued to his wife, Kathleen Schmainda (together the “CLN Shares“).

 

Following the above transactions, Trevor Brown will hold 45,761,083 Ordinary Shares, representing approximately 23.23 per cent. of the Company’s enlarged issued share capital. In addition, Kathleen Schmainda, who is also a consultant and existing shareholder in IQ-AI, will hold 10,302,081 Ordinary Shares, representing approximately 5.23 per cent. of the Company’s enlarged issued share capital.  

 

IQ-AI has no outstanding convertible loan notes following the above conversions. 

 

An application will be made for 6,304,914 CLN Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing (“Admission”) and it is expected that Admission will become effective and that dealing in the CLN Shares will commence on or around 8am on 19 January 2024. The CLN Shares will rank pari passu with the existing ordinary shares of the Company.

 

Following Admission, the Company will have 196,976,456 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company will be 196,976,456.

 

The above figure of 196,976,456 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

 

–ENDS-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

 

IQ-AI Ltd

Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website atwww.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.

 

 PDMR DEALINGS

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Trevor Brown

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Ltd

b)

LEI

213800SPW48XRJS2QH57

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of £0.01 each

 

 

 

ISIN:     JE00BD4H0R42

b)

Nature of the transaction

Conversion of convertible loan notes

c)

Price(s) and volume(s)

Exercise price of each convertible loan note :1.5p

Volume: 5,111,233

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

15 January 2024

f)

Place of the transaction

Main Market

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Schmainda

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Ltd

b)

LEI

213800SPW48XRJS2QH57

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of £0.01 each

 

 

 

ISIN:     JE00BD4H0R42

b)

Nature of the transaction

Conversion of convertible loan notes

c)

Price(s) and volume(s)

Exercise price of each convertible loan note :2p

Volume: 1,193,681

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

15 January 2024

f)

Place of the transaction

Main Market

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Article source

Recent Posts

  • Board Appointment

    /**/ RNS Number : 6987T Imaging Biometrics Limi...
  • Update and IB Nimble Webinar – 27 February 2026

    /**/ RNS Number : 4979S Imaging Biometrics Limi...
  • IBAI: Strategic Direction Fueling Organic Growth

    /**/ RNS Number : 1365P Imaging Biometrics Limi...
  • Expansion Global Distribution Agreement with GE

    /**/ RNS Number : 0116L Imaging Biometrics Limi...
  • Release of Next-Generation IB Clinic

    /**/ RNS Number : 1481J Imaging Biometrics Limi...
  • Policies
  • Investor Information

investor@imagingbiometrics.com

IFC5
St Helier, Jersey, Channel Islands
JE1 1ST

Copyright © 2015-2026 Imaging Biometrics Ltd. All Rights Reserved. Imaging Biometrics is a trademark of Imaging Biometrics, LLC.
TOP
Our website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT